Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Tomer Adar, David M. Faleck, Saranya Sasidharan, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 49, Iss. 7, pp. 873-879
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Virginia Solitano, Antonio Facciorusso, Tine Jess, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 4, pp. 907-921.e2
Closed Access | Times Cited: 59
Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies
Fabio Salvatore Macaluso, Marco Ventimiglia, Ambrogio Orlando
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1217-1227
Closed Access | Times Cited: 18
Management of inflammatory bowel disease in the elderly: A review
Paula Sousa, Lorenzo Bertani, Cláudio Rodrigues
Digestive and Liver Disease (2023) Vol. 55, Iss. 8, pp. 1001-1009
Open Access | Times Cited: 17
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study
Tom Holvoet, Marie Truyens, Cara De Galan, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 365-365
Open Access | Times Cited: 7
Main Disorders of Gastrointestinal Tract in Older People: An Overview
Antonella Gallo, Simona Pellegrino, Erika Pero, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 1, pp. 313-336
Open Access | Times Cited: 6
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review
Ashwin N. Ananthakrishnan, Geoffrey C. Nguyen, Çharles N. Bernstein
Gastroenterology (2020) Vol. 160, Iss. 1, pp. 445-451
Open Access | Times Cited: 49
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study
Nathaniel A. Cohen, Nikolas Plevris, Uri Kopylov, et al.
United European Gastroenterology Journal (2020) Vol. 8, Iss. 9, pp. 1076-1085
Open Access | Times Cited: 45
Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn’s Disease Patients
Rajat Garg, Manik Aggarwal, Robert S. Butler, et al.
Digestive Diseases and Sciences (2021) Vol. 67, Iss. 7, pp. 3138-3147
Open Access | Times Cited: 33
Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults
Bharati Kochar, Virginia Pate, Michael D. Kappelman, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 6, pp. 1299-1305.e5
Open Access | Times Cited: 33
Frailty in inflammatory bowel diseases: an emerging concept
Bharati Kochar, Ariela R. Orkaby, Ashwin N. Ananthakrishnan, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 33
Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases
David Cheng, Bharati Kochar, Tianxi Cai, et al.
The American Journal of Gastroenterology (2022) Vol. 117, Iss. 11, pp. 1845-1850
Open Access | Times Cited: 23
Positioning Therapies in the Management of Crohn’s Disease
Nghia Nguyen, Siddharth Singh, William J. Sandborn
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 6, pp. 1268-1279
Open Access | Times Cited: 40
Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric
Siddharth Singh, Sherman Picardo, Cynthia H. Seow
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 6, pp. 1367-1380
Open Access | Times Cited: 38
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
Renato Sablich, Maria Teresa Urbano, Marco Scarpa, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Indications and safety of newer IBD treatments in the older patient
Benjamin Clément, Kara De Felice, Anita Afzali
Current Gastroenterology Reports (2023) Vol. 25, Iss. 7, pp. 160-168
Open Access | Times Cited: 12
Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review
Anders Forss, Paulina Flis, Adonis Sotoodeh, et al.
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 7, pp. 821-829
Open Access | Times Cited: 4
Inflammatory Bowel Diseases in the Elderly: A Focus on Disease Characteristics and Biological Therapy Patterns
Renata Talar‐Wojnarowska, M Caban, Marta Jastrzębska, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 2767-2767
Open Access | Times Cited: 4
Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta-analysis
Yafang Li, Jin Ding, Chong Lu, et al.
Acta Pharmaceutica (2025)
Open Access
Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
Jean‐Frédéric LeBlanc, Daniel Wiseman, Péter L. Lakatos, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 30, pp. 4158-4171
Open Access | Times Cited: 35
Crohn’s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population‐based study
Hosim Soh, Jong Pil Im, Kyungdo Han, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 51, Iss. 4, pp. 446-456
Closed Access | Times Cited: 34
IBD in the Elderly: Management Challenges and Therapeutic Considerations
Vivy Tran, Berkeley N. Limketkai, Jenny Sauk
Current Gastroenterology Reports (2019) Vol. 21, Iss. 11
Closed Access | Times Cited: 33
Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
Sara Rundquist, Michael C. Sachs, Carl Eriksson, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 53, Iss. 4, pp. 471-483
Open Access | Times Cited: 31
Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study
Fabio Salvatore Macaluso, Walter Fries, Sara Renna, et al.
United European Gastroenterology Journal (2020) Vol. 8, Iss. 9, pp. 1045-1055
Open Access | Times Cited: 30
The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management
Simon Hong, Seymour Katz
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 24
How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease
Viviana Laredo, Carla J. Gargallo-Puyuelo, Fernando Gomollón
Journal of Clinical Medicine (2022) Vol. 11, Iss. 3, pp. 829-829
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top